Biotechnology
Compare Stocks
3 / 10Stock Comparison
FTRE vs IQV vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
FTRE vs IQV vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $1.47B | $30.32B | $8.98B |
| Revenue (TTM) | $2.71B | $16.63B | $4.03B |
| Net Income (TTM) | $-447M | $1.39B | $-185M |
| Gross Margin | 12.1% | 26.1% | 24.9% |
| Operating Margin | -1.1% | 13.9% | 11.8% |
| Forward P/E | 23.0x | 14.1x | 16.4x |
| Total Debt | $68M | $16.17B | $3.07B |
| Cash & Equiv. | $175M | $1.98B | $214M |
FTRE vs IQV vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 23 | May 26 | Return |
|---|---|---|---|
| Fortrea Holdings In… (FTRE) | 100 | 45.8 | -54.2% |
| IQVIA Holdings Inc. (IQV) | 100 | 79.5 | -20.5% |
| Charles River Labor… (CRL) | 100 | 86.5 | -13.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FTRE vs IQV vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FTRE is the clearest fit if your priority is momentum.
- +176.6% vs IQV's +16.5%
IQV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.33
- Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
- 166.5% 10Y total return vs CRL's 119.2%
CRL is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.52, Low D/E 95.5%, current ratio 1.29x
- Beta 1.52, current ratio 1.29x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 5.9% revenue growth vs CRL's -0.9% | |
| Value | Lower P/E (14.1x vs 16.4x) | |
| Quality / Margins | 8.3% margin vs FTRE's -16.5% | |
| Stability / Safety | Beta 1.33 vs FTRE's 2.35 | |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) | +176.6% vs IQV's +16.5% | |
| Efficiency (ROA) | 4.7% ROA vs FTRE's -16.3%, ROIC 8.7% vs -1.6% |
FTRE vs IQV vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FTRE vs IQV vs CRL — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
IQV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 6.1x FTRE's $2.7B. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to FTRE's -16.5%. On growth, IQV holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $2.7B | $16.6B | $4.0B |
| EBITDAEarnings before interest/tax | $48M | $3.5B | $757M |
| Net IncomeAfter-tax profit | -$447M | $1.4B | -$185M |
| Free Cash FlowCash after capex | $215M | $2.7B | $391M |
| Gross MarginGross profit ÷ Revenue | +12.1% | +26.1% | +24.9% |
| Operating MarginEBIT ÷ Revenue | -1.1% | +13.9% | +11.8% |
| Net MarginNet income ÷ Revenue | -16.5% | +8.3% | -4.6% |
| FCF MarginFCF ÷ Revenue | +8.0% | +16.1% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.3% | +8.4% | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | +15.0% | -160.0% |
Valuation Metrics
IQV leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, IQV's 13.0x EV/EBITDA is more attractive than FTRE's 28.8x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $1.5B | $30.3B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $44.5B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | 22.79x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | 23.00x | 14.06x | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.56x | — |
| EV / EBITDAEnterprise value multiple | 28.82x | 12.97x | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 0.54x | 1.86x | 2.24x |
| Price / BookPrice ÷ Book value/share | 2.52x | 4.67x | 2.81x |
| Price / FCFMarket cap ÷ FCF | 16.68x | 14.78x | 17.31x |
Profitability & Efficiency
IQV leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-79 for FTRE. FTRE carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -79.1% | +22.1% | -5.7% |
| ROA (TTM)Return on assets | -16.3% | +4.7% | -2.5% |
| ROICReturn on invested capital | -1.6% | +8.7% | +6.3% |
| ROCEReturn on capital employed | -1.4% | +11.0% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.12x | 2.44x | 0.95x |
| Net DebtTotal debt minus cash | -$107M | $14.2B | $2.9B |
| Cash & Equiv.Liquid assets | $175M | $2.0B | $214M |
| Total DebtShort + long-term debt | $68M | $16.2B | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | -7.33x | 3.10x | 6.38x |
Total Returns (Dividends Reinvested)
Evenly matched — FTRE and IQV and CRL each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IQV five years ago would be worth $7,621 today (with dividends reinvested), compared to $4,866 for FTRE. Over the past 12 months, FTRE leads with a +176.6% total return vs IQV's +16.5%. The 3-year compound annual growth rate (CAGR) favors CRL at -1.4% vs FTRE's -21.3% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -7.4% | -20.7% | -10.1% |
| 1-Year ReturnPast 12 months | +176.6% | +16.5% | +32.8% |
| 3-Year ReturnCumulative with dividends | -51.3% | -5.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | -51.3% | -23.8% | -46.9% |
| 10-Year ReturnCumulative with dividends | -51.3% | +166.5% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -21.3% | -2.0% | -1.4% |
Risk & Volatility
Evenly matched — FTRE and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
IQV is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than FTRE's 2.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FTRE currently trades 83.4% from its 52-week high vs IQV's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.35x | 1.33x | 1.52x |
| 52-Week HighHighest price in past year | $18.67 | $247.05 | $228.88 |
| 52-Week LowLowest price in past year | $3.97 | $134.65 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +72.3% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 82.8 | 58.5 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 1.6M | 806K |
Analyst Outlook
IQV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: FTRE as "Hold", IQV as "Buy", CRL as "Buy". Consensus price targets imply 26.3% upside for IQV (target: $226) vs 12.9% for CRL (target: $205).
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $18.83 | $225.63 | $205.43 |
| # AnalystsCovering analysts | 12 | 44 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% | +4.0% |
IQV leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
FTRE vs IQV vs CRL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FTRE or IQV or CRL a better buy right now?
For growth investors, IQVIA Holdings Inc.
(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FTRE or IQV or CRL?
On forward P/E, IQVIA Holdings Inc.
is actually cheaper at 14. 1x.
03Which is the better long-term investment — FTRE or IQV or CRL?
Over the past 5 years, IQVIA Holdings Inc.
(IQV) delivered a total return of -23. 8%, compared to -51. 3% for Fortrea Holdings Inc. (FTRE). Over 10 years, the gap is even starker: IQV returned +166. 5% versus FTRE's -51. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FTRE or IQV or CRL?
By beta (market sensitivity over 5 years), IQVIA Holdings Inc.
(IQV) is the lower-risk stock at 1. 33β versus Fortrea Holdings Inc. 's 2. 35β — meaning FTRE is approximately 77% more volatile than IQV relative to the S&P 500. On balance sheet safety, Fortrea Holdings Inc. (FTRE) carries a lower debt/equity ratio of 12% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — FTRE or IQV or CRL?
By revenue growth (latest reported year), IQVIA Holdings Inc.
(IQV) is pulling ahead at 5. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FTRE or IQV or CRL?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus -36. 2% for Fortrea Holdings Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -1. 1% for FTRE. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FTRE or IQV or CRL more undervalued right now?
On forward earnings alone, IQVIA Holdings Inc.
(IQV) trades at 14. 1x forward P/E versus 23. 0x for Fortrea Holdings Inc. — 8. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.
08Which pays a better dividend — FTRE or IQV or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FTRE or IQV or CRL better for a retirement portfolio?
For long-horizon retirement investors, IQVIA Holdings Inc.
(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+166. 5% 10Y return). Fortrea Holdings Inc. (FTRE) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +166. 5%, FTRE: -51. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FTRE and IQV and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.